Publication | Closed Access

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Hematological MalignancyDouble-blind Phase 3MedicineDexamethasone Versus PlaceboHematologyClinical TrialsMyeloid NeoplasiaPharmacotherapyOncologyRadiation OncologyRefractory Multiple MyelomaHealth Sciences